Literature DB >> 716765

Long-term application of intermittent urethral catheterization to the neurogenic bladder of diabetes mellitus.

P T Chandler, P R Rege, R A Knoblaugh.   

Abstract

Two case reports are presented of patients who utilized long-term intermittent urethral catheterization as a primary management of diabetic neurogenic bladder. The results indicate fewer complications than with a continuous indwelling Foley catheter. Further, only two urinary tract infections occurred during 39 months of patients utilization. No renal or vesical lithiasis occurred. One patient had a remission and went on drug therapy alone. The other patient may use this technique indefinitely.

Entities:  

Mesh:

Year:  1978        PMID: 716765     DOI: 10.1007/bf02581013

Source DB:  PubMed          Journal:  Acta Diabetol Lat        ISSN: 0001-5563


  8 in total

1.  The bladder in diabetes.

Authors:  P J Watkins
Journal:  Practitioner       Date:  1975-01

2.  The practical urological management of the patient with spinal cord injury.

Authors:  A E COMARR
Journal:  Br J Urol       Date:  1959-03

3.  DISCUSSION ON THE TREATMENT AND PROGNOSIS OF TRAUMATIC PARAPLEGIA.

Authors: 
Journal:  Proc R Soc Med       Date:  1947-03

Review 4.  [Visceral diabetic neuropathy].

Authors:  M Jadzinsky; I Faerman; D Fox
Journal:  Acta Diabetol Lat       Date:  1973 Mar-Apr

5.  Neurogenic vesical dysfunction in diabetes mellitus: another look at vesical neck resection.

Authors:  H Zincke; J T Campbell; P J Palumbo; W L Furlow
Journal:  J Urol       Date:  1974-04       Impact factor: 7.450

6.  Urinary tract sterility and indwelling catheters.

Authors:  R S Malek; W H Boyce; R M Wilkiemeyer
Journal:  J Urol       Date:  1973-01       Impact factor: 7.450

7.  Intermittent catheterization for the traumatic cord bladder patient.

Authors:  A E Comarr
Journal:  J Urol       Date:  1972-07       Impact factor: 7.450

8.  Intermittent catheterization in paraplegic patients.

Authors:  E Bors
Journal:  Urol Int       Date:  1967       Impact factor: 2.089

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.